Xencor’s XmAb™ Technology Wins Wall Street Journal 2006 Technology Innovation Award Read more about Xencor’s XmAb™ Technology Wins Wall Street Journal 2006 Technology Innovation Award
Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures Read more about Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures
Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement Read more about Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement
Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease Read more about Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease
Xencor Selects Antibody Development Candidates Read more about Xencor Selects Antibody Development Candidates
Xencor Expands Series E Financing to $60 Million Read more about Xencor Expands Series E Financing to $60 Million
Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings Read more about Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings
Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer Read more about Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer
Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting Read more about Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting
Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology Read more about Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology
